Ignite Creation Date:
2025-12-25 @ 12:55 AM
Ignite Modification Date:
2026-03-11 @ 10:28 PM
Study NCT ID:
NCT02013167
Status:
TERMINATED
Last Update Posted:
2024-03-05
First Post:
2013-12-03
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Sponsor:
Amgen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
00103311
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None